Inclusion Criteria:  Diagnosis of T2D Age between 25 and 75 years HbA1c ≥6.5 and ≤9.5 % BMI ≤ 45 kg/m2 Treatment-naive or stable antihyperglycemic therapy with metformin, α-glucosidase-inhibitor and/or SGLT2 inhibitor Ability to give consent  Exclusion Criteria:  Acute infections (hsCRP > 5mg/dl, body temperature >37.5°C) Insulin therapy or treatment with sulfonylureas, glinides, GLP-1 receptor agonists, thiazolidinediones; current treatment with DPP-4 inhibitors or during the 4 weeks prior to baseline examination Uncontrolled hyperglycemia, e.g. fasting blood glucose >240 mg/dl Heart rate <50 or >100 beats per minute; systolic blood pressure <100 or >160 mmHg; diastolic blood pressure <50 or >100 mmHg; uncontrolled hypertension Creatinine clearance <60 ml/min (eGFR by MDRD formula) Severe chronic illnesses, such as congestive heart failure (NYHA III/IV), liver insufficiency (Child-Pugh Class B/C), history of acute coronary syndrome, stroke Anemia (Hb <12 g/l for men, Hb <11 g/l for women) Participation in another intervention study within 2 months before the examination Hypersensitivity against AP-325, placebo or other ingredients of IMP Immunocompromising diseases Immunomodulatory drugs (e.g. oral cortisone preparations, biologicals) Thyroid diseases with an unstable metabolic state (change in L-thyroxine dose within the past 6 weeks, TSH and fT4 outside the normal range) Planned pregnancy, pregnant or lactating women, positive pregnancy test, and woman of childbearing potential not using two adequate methods of contraception, including a barrier method and a highly efficacious non-barrier method Past (≤ 5 years) or current history of psychiatric disorders, including psychiatric depression HIV, hepatitis B or C disease Previous / current alcohol and / or drug abuse Malignant cancer BIA and MR-incompatible metal or magnetic implants, devices or objects inside of or on the body, claustrophobia Treatment with the following drug groups or agents:  Anticoagulant drugs (exception: acetylsalicylic acid 100 mg/day), dihydropyridines (e.g. nifedipine, amlodipine), azilsartan, losartan and irbesartan, celecoxib; if applicable, other drugs that are predominantly metabolized by CYP2C9  Inhibitors or inducers of CYP2C9, CYP3A4, such as amiodarone, verapamil, rifampicin Poor CYP2C9 metabolizer